Domantis
Domain antibody technology
Domantis was founded as Diversys Limited in December 2000 by Greg Winter and Ian Tomlinson of the UK Medical Research Council’s (MRC) Laboratory of Molecular Biology with the backing of the MRC and MVM Limited.
In April 2001, Domantis raised a total of USD 20 million through a strategic collaboration and investment with the Australian biotechnology company Peptech Limited and an additional investment by MVM Limited.
Robert Connelly (CEO)
Ian Tomlinson (CSO)
Pamela Hay (CCO)
Mark Skaletsky (Chairman)
David Brister
Sir Gregory Winter Ph.D., CBE, FRS
Mel Bridges
Sir Ravinder Maini, FRCP, FRCP(E), FMedSci
Nigel Pitchford, MBA, Ph.D.
Robert Connelly
Ian Tomlinson
Steve Holmes, Ph.D.
Jasper Clube, EPA, CPA
Neil Brewis, Ph.D.
Laurent Jespers, Ph.D.
200 Fifth Avenue
Waltham, MA 02451
USA
Phone +1-781-250-2833
Fax: +1-781-250-2834
Domantis is using its Domain Antibodies as therapeutics for the treatment of cancer and inflammatory diseases.
Related patents
- Method to screen phage display libraries with different ligands
- Selection system
- SELECTION SYSTEM FOR PHAGEMIDS USING PROTEOLYTICALLY SENSITIVE HELPER PHAGE
- Method to screen phage display libraries with different ligands
- NAIVE SCREENING METHOD
- Matrix sreening methods
- Direct screening method
- Combinatorial protein domains
- Matrix screening method
- Nucleic acids, proteins, and screening methods
- Ligand
- Method to screen phage display libraries with different ligands
- Ligand
- Compositions and methods for treating inflammatory disorders
- Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor